RephImmune has been selected as a member of the Taiwan delegation for the 2024 SelectUSA Investment Summit. 

Led by the TAcc+ accelerator, twenty Taiwanese companies from various industries will travel to Washington, D.C., to attend the 10th SelectUSA Investment Summit from June 23 to 26. This summit is the premier event for promoting investment in the United States, serving as a bridge between global companies and economic development organizations across the U.S. 

RephImmune has been selected as a finalist for the 2024 MassChallenge Switzerland Accelerator. 

MassChallenge is renowned as one of the world's most prestigious accelerators, and Switzerland is a leading nation in biotechnology and cell & gene therapy. In 2024, MassChallenge Switzerland selected 103 startups from over 1,300 global applicants through a rigorous selection process, representing the top 8% of all applicants. As the only representative from Taiwan, RephImmune's innovative engineered cell therapy has been recognized and honored to join this esteemed group.